Teva Israel, a subsidiary of Teva Pharmaceutical Industries Ltd., recently announced a distribution and cooperation agreement with Syqe Medical, a Tel Aviv company that developed an inhaler for administering marijuana in precise doses. The dose can be tailored to each patient like a standard medical treatment, which experts say should reduce or eliminate the objections of reluctant physicians.

Read more on the New York Times here.